Shai S. Erlich
Directeur Technique/Scientifique/R&D chez Quark Pharmaceuticals, Inc.
Profil
Shai S.
Erlich is currently the President-US Operations & Chief Medical Officer at Quark Pharmaceuticals, Inc. He started this position in 2010.
Prior to his current role, he has a background in education, having obtained a graduate degree from Tel-Aviv University, an undergraduate degree from Ben-Gurion University of the Negev, and a doctorate degree from Icahn School of Medicine at Mount Sinai.
Postes actifs de Shai S. Erlich
| Sociétés | Poste | Début |
|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Directeur Technique/Scientifique/R&D | 27/09/2010 |
Formation de Shai S. Erlich
| Ben-Gurion University of the Negev | Undergraduate Degree |
| Tel-Aviv University | Graduate Degree |
| Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |